Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses – results from two phase 2b randomized trials in adolescents-Reference-Cited by-同舟云学术

Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses – results from two phase 2b randomized trials in adolescents

Published:2021-09-28 Issue:11 Volume:17 Page:4689-4700
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Vesikari Timo¹,Brzostek Jerzy²,Ahonen Anitta³,Paassilta Marita⁴,Majda-Stanislawska Ewa⁵,Szenborn Leszek⁶^ORCID,Virta Miia³,Clifford Robert⁷^ORCID,Jackowska Teresa⁸,Kimmel Murray⁹,Bindi Ilaria¹⁰,Keshavan Pavitra¹⁰,Pedotti Paola¹¹,Toneatto Daniela¹⁰^ORCID

Affiliation:

1. Nordic Research Network Oy, Tampere, Finland

2. Health Care Establishment in Debica, Infectious Diseases Outpatient Clinic, Debica, Poland

3. Vaccine Research Center, Tampere University, Tampere, Finland

4. Tampere University and Tampere University Hospital, Tampere, Finland

5. Department of Pediatric Infectious Diseases, Medical University of Lodz, Lodz, Poland

6. Department of Pediatric Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland

7. Coastal Pediatric Research, Charleston, SC, USA

8. Department of Pediatrics, The Medical Centre of Postgraduate Education, Warsaw, Poland

9. Optimal Research LLC, Melbourne, FL, USA

10. Gsk, Siena, Italy

11. Gsk, Amsterdam, The Netherlands

Funder

GSK group of companies

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2021.1968214

Reference52 articles.

1. World Health Organization. Meningococcal meningitis. Key facts. 2018 Feb 19 [accessed 2019 Feb]. https://www.who.int/en/news-room/fact-sheets/detail/meningococcal-meningitis.

2. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2017. 2019 May 31 [accessed 2020 Feb]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2017.pdf.

3. European Center for Disease Prevention and Control. Surveillance report. annual epidemiological report for 2016. Invasive meningococcal disease. Stockholm; 2018.

4. European Center for Disease Prevention and Control. Factsheet about meningococcal disease. 2019 Jan 7 [accessed 2019 Feb]. https://ecdc.europa.eu/en/meningococcal-disease/factsheet.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination;Expert Review of Vaccines;2024-06-07

2. Recent advances in various bio-applications of bacteria-derived outer membrane vesicles;Microbial Pathogenesis;2023-12

3. Non-clinical evaluation of local and systemic immunity induced by different vaccination strategies of the candidate tuberculosis vaccine M72/AS01;Tuberculosis;2023-12

4. A comparison of national vaccination policies to prevent serogroup B meningococcal disease;Vaccine;2022-06

5. Meningococcal Disease and Immunization Activities in Hajj and Umrah Pilgrimage: a review;Infectious Diseases and Therapy;2022-05-19